Last reviewed · How we verify
Isovue
At a glance
| Generic name | Isovue |
|---|---|
| Also known as | IOPAMIDOL injection |
| Sponsor | Bracco Diagnostics, Inc |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer (PHASE1)
- Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy (PHASE2)
- ISOVUE Comparative Trial (NA)
- Thyroid Function of Pediatric Subjects Following Isovue® Administration (PHASE4)
- PericOronary INflammaTion in Non-Obstructive Coronary Artery Disease
- Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis (NA)
- Adenosine Contrast CorrELations in Evaluating RevAscularizaTION (PHASE4)
- Dynamic Computed Tomography Myocardial Perfusion Imaging for Detection of Coronary Artery Disease (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isovue CI brief — competitive landscape report
- Isovue updates RSS · CI watch RSS
- Bracco Diagnostics, Inc portfolio CI